Revenue Breakdown
Composition ()
No data
Revenue Streams
Eli Lilly and Co (LLY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diabetes-Mounjaro, accounting for 37.0% of total sales, equivalent to $6.52B. Other significant revenue streams include Diabetes-Zepbound and Oncology-Verzenio. Understanding this composition is critical for investors evaluating how LLY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Eli Lilly and Co maintains a gross margin of 82.52%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 46.59%, while the net margin is 34.41%. These profitability ratios, combined with a Return on Equity (ROE) of 101.36%, provide a clear picture of how effectively LLY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LLY competes directly with industry leaders such as NVO and RDY. With a market capitalization of $992.40B, it holds a leading position in the sector. When comparing efficiency, LLY's gross margin of 82.52% stands against NVO's 80.86% and RDY's 53.63%. Such benchmarking helps identify whether Eli Lilly and Co is trading at a premium or discount relative to its financial performance.
